Please wait while you are redirected to the right page...
Please share your location to continue
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy.
![The new entity will be publicly traded and will focus on orphan drugs. [© Sergey Ilin - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June13_2011_18890711_RubberManRedPiePiece_SynagevaTrimerisMerger2313447113-324x160.jpg "Synageva Merges with Trimeris in All-Stock Deal")
![Funds will be used to continue clinical development of lead LAL deficiency enzyme replacement therapy.[© Bobby4237 - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesMarch2011March21_2011_Spreadof100dollarbills_SynagevaFinancing2005712466-324x160.jpg "Synageva Raises $25M Through Private Placement with Existing Investors")
![Pharmacological chaperone is designed to stabilize a-GAL A and restore its activity.[Sergey Ilin-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesOct2010Oct29_18890711_RubberManRedPiePiece_GSKtakesStakeinAmicusforFabryDisease5122732422-324x160.jpg "GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug")
